212 related articles for article (PubMed ID: 28188500)
1. Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.
Madu MF; Deken MM; van der Hage JA; Jóźwiak K; Wouters MWJM; van Akkooi ACJ
Ann Surg Oncol; 2017 Jul; 24(7):1997-2005. PubMed ID: 28188500
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
3. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
4. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
Tulokas SKA; Kohtamäki LM; Mäkelä SP; Juteau S; Albäck A; Vikatmaa PJ; Mattila KE; Skyttä TK; Koivunen JP; Tyynelä-Korhonen K; Hernberg MM
Melanoma Res; 2021 Oct; 31(5):456-463. PubMed ID: 34132224
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
7. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
[TBL] [Abstract][Full Text] [Related]
8. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
Olofsson R; Mattsson J; Lindnér P
Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
[TBL] [Abstract][Full Text] [Related]
10. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.
Moreno-Ramirez D; de la Cruz-Merino L; Ferrandiz L; Villegas-Portero R; Nieto-Garcia A
Oncologist; 2010; 15(4):416-27. PubMed ID: 20348274
[TBL] [Abstract][Full Text] [Related]
12. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
Belgrano V; Pettersson J; Nilsson JA; Mattsson J; Katsarelias D; Olofsson Bagge R
Ann Surg Oncol; 2019 Apr; 26(4):1055-1062. PubMed ID: 30617871
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma.
Lindnér P; Doubrovsky A; Kam PC; Thompson JF
Ann Surg Oncol; 2002 Mar; 9(2):127-36. PubMed ID: 11888868
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
15. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion.
Bagge AS; Ben-Shabat I; Belgrano V; Olofsson Bagge R
Ann Surg Oncol; 2016 Jun; 23(6):2062-9. PubMed ID: 26868956
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Ann Surg Oncol; 2002 Dec; 9(10):968-74. PubMed ID: 12464588
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
Koops HS; Vaglini M; Suciu S; Kroon BB; Thompson JF; Göhl J; Eggermont AM; Di Filippo F; Krementz ET; Ruiter D; Lejeune FJ
J Clin Oncol; 1998 Sep; 16(9):2906-12. PubMed ID: 9738557
[TBL] [Abstract][Full Text] [Related]
20. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Grünhagen DJ; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg; 2004 Dec; 240(6):939-47; discussion 947-8. PubMed ID: 15570199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
